Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy—A Systematic Review

Christian B. van der Pol, Christopher S. Lim, Claude B. Sirlin, Trevor A. McGrath, Jean Paul Salameh, Mustafa R. Bashir, An Tang, Amit Singal, Andreu F. Costa, Kathryn Fowler, Matthew D.F. McInnes

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background & Aims: The Liver Imaging Reporting and Data System (LI-RADS) categorizes observations from imaging analyses of high-risk patients based on the level of suspicion for hepatocellular carcinoma (HCC) and overall malignancy. The categories range from definitely benign (LR-1) to definitely HCC (LR-5), malignancy (LR-M), or tumor in vein (LR-TIV) based on findings from computed tomography or magnetic resonance imaging. However, the actual percentage of HCC and overall malignancy within each LI-RADS category is not known. We performed a systematic review to determine the percentage of observations in each LI-RADS category for computed tomography and magnetic resonance imaging that are HCCs or malignancies. Methods: We searched the MEDLINE, Embase, Cochrane CENTRAL, and Scopus databases from 2014 through 2018 for studies that reported the percentage of observations in each LI-RADS v2014 and v2017 category that were confirmed as HCCs or other malignancies based on pathology, follow-up imaging analyses, or response to treatment (reference standard). Data were assessed on a per-observation basis. Random-effects models were used to determine the pooled percentages of HCC and overall malignancy for each LI-RADS category. Differences between categories were compared by analysis of variance of logit-transformed percentage of HCC and overall malignancy. Risk of bias and concerns about applicability were assessed with the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Results: Of 454 studies identified, 17 (all retrospective studies) were included in the final analysis, consisting of 2760 patients, 3556 observations, and 2482 HCCs. The pooled percentages of observations confirmed as HCC and overall malignancy, respectively, were 94% (95% confidence interval [CI] 92%–96%) and 97% (95% CI 95%–99%) for LR-5, 74% (95% CI 67%–80%) and 80% (95% CI 75%–85%) for LR-4, 38% (95% CI 31%–45%) and 40% (95% CI 31%–50%) for LR-3, 13% (95% CI 8%–22%) and 14% (95% CI 9%–21%) for LR-2, 79% (95% CI 63%–89%) and 92% (95% CI 77%–98%) for LR-TIV, and 36% (95% CI 26%–48%) and 93% (95% CI 87%–97%) for LR-M. No malignancies were found in the LR-1 group. The percentage of HCCs and overall malignancies confirmed differed significantly among LR groups 2–5 (P <.00001). Patient selection was the most frequent factor that affected bias risk, because of verification bias and case–control study design. Conclusions: In a systematic review, we found that increasing LI-RADS categories contained increasing percentages of HCCs and overall malignancy based on reference standard confirmation. Of observations categorized as LR-M, 93% were malignancies and 36% were confirmed as HCCs. The percentage of HCCs found in the LR-2 and LR-3 categories indicate the need for a more active management strategy than currently recommended. Prospective studies are needed to validate these findings. PROSPERO number CRD42018087441.

Original languageEnglish (US)
Pages (from-to)976-986
Number of pages11
JournalGastroenterology
Volume156
Issue number4
DOIs
StatePublished - Mar 1 2019

Fingerprint

Information Systems
Hepatocellular Carcinoma
Magnetic Resonance Spectroscopy
Tomography
Liver
Confidence Intervals
Neoplasms
Veins
Magnetic Resonance Imaging
MEDLINE
Patient Selection
Analysis of Variance
Retrospective Studies

Keywords

  • Computed Tomography
  • Liver Cancer
  • Magnetic Resonance Imaging
  • Risk Assessment

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy—A Systematic Review. / van der Pol, Christian B.; Lim, Christopher S.; Sirlin, Claude B.; McGrath, Trevor A.; Salameh, Jean Paul; Bashir, Mustafa R.; Tang, An; Singal, Amit; Costa, Andreu F.; Fowler, Kathryn; McInnes, Matthew D.F.

In: Gastroenterology, Vol. 156, No. 4, 01.03.2019, p. 976-986.

Research output: Contribution to journalArticle

van der Pol, Christian B. ; Lim, Christopher S. ; Sirlin, Claude B. ; McGrath, Trevor A. ; Salameh, Jean Paul ; Bashir, Mustafa R. ; Tang, An ; Singal, Amit ; Costa, Andreu F. ; Fowler, Kathryn ; McInnes, Matthew D.F. / Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy—A Systematic Review. In: Gastroenterology. 2019 ; Vol. 156, No. 4. pp. 976-986.
@article{7f2cd4a658654656842c1f75d13cbd43,
title = "Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy—A Systematic Review",
abstract = "Background & Aims: The Liver Imaging Reporting and Data System (LI-RADS) categorizes observations from imaging analyses of high-risk patients based on the level of suspicion for hepatocellular carcinoma (HCC) and overall malignancy. The categories range from definitely benign (LR-1) to definitely HCC (LR-5), malignancy (LR-M), or tumor in vein (LR-TIV) based on findings from computed tomography or magnetic resonance imaging. However, the actual percentage of HCC and overall malignancy within each LI-RADS category is not known. We performed a systematic review to determine the percentage of observations in each LI-RADS category for computed tomography and magnetic resonance imaging that are HCCs or malignancies. Methods: We searched the MEDLINE, Embase, Cochrane CENTRAL, and Scopus databases from 2014 through 2018 for studies that reported the percentage of observations in each LI-RADS v2014 and v2017 category that were confirmed as HCCs or other malignancies based on pathology, follow-up imaging analyses, or response to treatment (reference standard). Data were assessed on a per-observation basis. Random-effects models were used to determine the pooled percentages of HCC and overall malignancy for each LI-RADS category. Differences between categories were compared by analysis of variance of logit-transformed percentage of HCC and overall malignancy. Risk of bias and concerns about applicability were assessed with the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Results: Of 454 studies identified, 17 (all retrospective studies) were included in the final analysis, consisting of 2760 patients, 3556 observations, and 2482 HCCs. The pooled percentages of observations confirmed as HCC and overall malignancy, respectively, were 94{\%} (95{\%} confidence interval [CI] 92{\%}–96{\%}) and 97{\%} (95{\%} CI 95{\%}–99{\%}) for LR-5, 74{\%} (95{\%} CI 67{\%}–80{\%}) and 80{\%} (95{\%} CI 75{\%}–85{\%}) for LR-4, 38{\%} (95{\%} CI 31{\%}–45{\%}) and 40{\%} (95{\%} CI 31{\%}–50{\%}) for LR-3, 13{\%} (95{\%} CI 8{\%}–22{\%}) and 14{\%} (95{\%} CI 9{\%}–21{\%}) for LR-2, 79{\%} (95{\%} CI 63{\%}–89{\%}) and 92{\%} (95{\%} CI 77{\%}–98{\%}) for LR-TIV, and 36{\%} (95{\%} CI 26{\%}–48{\%}) and 93{\%} (95{\%} CI 87{\%}–97{\%}) for LR-M. No malignancies were found in the LR-1 group. The percentage of HCCs and overall malignancies confirmed differed significantly among LR groups 2–5 (P <.00001). Patient selection was the most frequent factor that affected bias risk, because of verification bias and case–control study design. Conclusions: In a systematic review, we found that increasing LI-RADS categories contained increasing percentages of HCCs and overall malignancy based on reference standard confirmation. Of observations categorized as LR-M, 93{\%} were malignancies and 36{\%} were confirmed as HCCs. The percentage of HCCs found in the LR-2 and LR-3 categories indicate the need for a more active management strategy than currently recommended. Prospective studies are needed to validate these findings. PROSPERO number CRD42018087441.",
keywords = "Computed Tomography, Liver Cancer, Magnetic Resonance Imaging, Risk Assessment",
author = "{van der Pol}, {Christian B.} and Lim, {Christopher S.} and Sirlin, {Claude B.} and McGrath, {Trevor A.} and Salameh, {Jean Paul} and Bashir, {Mustafa R.} and An Tang and Amit Singal and Costa, {Andreu F.} and Kathryn Fowler and McInnes, {Matthew D.F.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1053/j.gastro.2018.11.020",
language = "English (US)",
volume = "156",
pages = "976--986",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy—A Systematic Review

AU - van der Pol, Christian B.

AU - Lim, Christopher S.

AU - Sirlin, Claude B.

AU - McGrath, Trevor A.

AU - Salameh, Jean Paul

AU - Bashir, Mustafa R.

AU - Tang, An

AU - Singal, Amit

AU - Costa, Andreu F.

AU - Fowler, Kathryn

AU - McInnes, Matthew D.F.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background & Aims: The Liver Imaging Reporting and Data System (LI-RADS) categorizes observations from imaging analyses of high-risk patients based on the level of suspicion for hepatocellular carcinoma (HCC) and overall malignancy. The categories range from definitely benign (LR-1) to definitely HCC (LR-5), malignancy (LR-M), or tumor in vein (LR-TIV) based on findings from computed tomography or magnetic resonance imaging. However, the actual percentage of HCC and overall malignancy within each LI-RADS category is not known. We performed a systematic review to determine the percentage of observations in each LI-RADS category for computed tomography and magnetic resonance imaging that are HCCs or malignancies. Methods: We searched the MEDLINE, Embase, Cochrane CENTRAL, and Scopus databases from 2014 through 2018 for studies that reported the percentage of observations in each LI-RADS v2014 and v2017 category that were confirmed as HCCs or other malignancies based on pathology, follow-up imaging analyses, or response to treatment (reference standard). Data were assessed on a per-observation basis. Random-effects models were used to determine the pooled percentages of HCC and overall malignancy for each LI-RADS category. Differences between categories were compared by analysis of variance of logit-transformed percentage of HCC and overall malignancy. Risk of bias and concerns about applicability were assessed with the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Results: Of 454 studies identified, 17 (all retrospective studies) were included in the final analysis, consisting of 2760 patients, 3556 observations, and 2482 HCCs. The pooled percentages of observations confirmed as HCC and overall malignancy, respectively, were 94% (95% confidence interval [CI] 92%–96%) and 97% (95% CI 95%–99%) for LR-5, 74% (95% CI 67%–80%) and 80% (95% CI 75%–85%) for LR-4, 38% (95% CI 31%–45%) and 40% (95% CI 31%–50%) for LR-3, 13% (95% CI 8%–22%) and 14% (95% CI 9%–21%) for LR-2, 79% (95% CI 63%–89%) and 92% (95% CI 77%–98%) for LR-TIV, and 36% (95% CI 26%–48%) and 93% (95% CI 87%–97%) for LR-M. No malignancies were found in the LR-1 group. The percentage of HCCs and overall malignancies confirmed differed significantly among LR groups 2–5 (P <.00001). Patient selection was the most frequent factor that affected bias risk, because of verification bias and case–control study design. Conclusions: In a systematic review, we found that increasing LI-RADS categories contained increasing percentages of HCCs and overall malignancy based on reference standard confirmation. Of observations categorized as LR-M, 93% were malignancies and 36% were confirmed as HCCs. The percentage of HCCs found in the LR-2 and LR-3 categories indicate the need for a more active management strategy than currently recommended. Prospective studies are needed to validate these findings. PROSPERO number CRD42018087441.

AB - Background & Aims: The Liver Imaging Reporting and Data System (LI-RADS) categorizes observations from imaging analyses of high-risk patients based on the level of suspicion for hepatocellular carcinoma (HCC) and overall malignancy. The categories range from definitely benign (LR-1) to definitely HCC (LR-5), malignancy (LR-M), or tumor in vein (LR-TIV) based on findings from computed tomography or magnetic resonance imaging. However, the actual percentage of HCC and overall malignancy within each LI-RADS category is not known. We performed a systematic review to determine the percentage of observations in each LI-RADS category for computed tomography and magnetic resonance imaging that are HCCs or malignancies. Methods: We searched the MEDLINE, Embase, Cochrane CENTRAL, and Scopus databases from 2014 through 2018 for studies that reported the percentage of observations in each LI-RADS v2014 and v2017 category that were confirmed as HCCs or other malignancies based on pathology, follow-up imaging analyses, or response to treatment (reference standard). Data were assessed on a per-observation basis. Random-effects models were used to determine the pooled percentages of HCC and overall malignancy for each LI-RADS category. Differences between categories were compared by analysis of variance of logit-transformed percentage of HCC and overall malignancy. Risk of bias and concerns about applicability were assessed with the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Results: Of 454 studies identified, 17 (all retrospective studies) were included in the final analysis, consisting of 2760 patients, 3556 observations, and 2482 HCCs. The pooled percentages of observations confirmed as HCC and overall malignancy, respectively, were 94% (95% confidence interval [CI] 92%–96%) and 97% (95% CI 95%–99%) for LR-5, 74% (95% CI 67%–80%) and 80% (95% CI 75%–85%) for LR-4, 38% (95% CI 31%–45%) and 40% (95% CI 31%–50%) for LR-3, 13% (95% CI 8%–22%) and 14% (95% CI 9%–21%) for LR-2, 79% (95% CI 63%–89%) and 92% (95% CI 77%–98%) for LR-TIV, and 36% (95% CI 26%–48%) and 93% (95% CI 87%–97%) for LR-M. No malignancies were found in the LR-1 group. The percentage of HCCs and overall malignancies confirmed differed significantly among LR groups 2–5 (P <.00001). Patient selection was the most frequent factor that affected bias risk, because of verification bias and case–control study design. Conclusions: In a systematic review, we found that increasing LI-RADS categories contained increasing percentages of HCCs and overall malignancy based on reference standard confirmation. Of observations categorized as LR-M, 93% were malignancies and 36% were confirmed as HCCs. The percentage of HCCs found in the LR-2 and LR-3 categories indicate the need for a more active management strategy than currently recommended. Prospective studies are needed to validate these findings. PROSPERO number CRD42018087441.

KW - Computed Tomography

KW - Liver Cancer

KW - Magnetic Resonance Imaging

KW - Risk Assessment

UR - http://www.scopus.com/inward/record.url?scp=85060144889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060144889&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2018.11.020

DO - 10.1053/j.gastro.2018.11.020

M3 - Article

VL - 156

SP - 976

EP - 986

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -